Screener
ANI Pharmaceuticals ANIP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current Liabilities | ||
| Accounts payable | $73,830 | $62,583 |
| Accrued royalties | 55,830 | 48,497 |
| Accrued compensation and related expenses | 27,154 | 37,897 |
| Accrued government rebates | 41,392 | 43,154 |
| Returned goods reserve | 44,013 | 49,504 |
| Accrued expenses and other | 16,575 | 16,970 |
| Income taxes payable | 3,532 | 2,239 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's accrued expenses?
- ANI Pharmaceuticals (ANIP) reported accrued expenses of $27.15M in Q2 2026.
- How has ANI Pharmaceuticals's accrued expenses changed year-over-year?
- ANI Pharmaceuticals's accrued expenses decreased by 17.5% year-over-year, from $32.93M to $27.15M.
- What is the long-term trend for ANI Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accrued expenses has grown at a 43.5% compound annual growth rate (CAGR), from $6.23M to $37.9M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about ANI Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude